Novo Nordisk suffers dual semaglutide patent setbacks in Europe
Novo Nordisk has lost a European semaglutide patent with the European Patent Office's Board of Appeal in a decision published Monday rejecting the Wegovy and Ozempic-maker's eleventh-hour effort to amend its...To view the full article, register now.
Already a subscriber? Click here to view full article